Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): Results of Phase I and II trials

Expert Opinion on Biological Therapy

Volumn 1, Issue 3, 2001, Pages 525-538

  Kirn, David ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Adenovlms; Cancer; Clinical research; Gene therapy; Viral therapy

Indexed keywords

ADENOVIRUS; CLINICAL TRIAL; DEFECTIVE VIRUS; DNA VECTOR; GENE THERAPY; GENETICS; HUMAN; METHODOLOGY; NEOPLASM; REVIEW; VIRUS REPLICATION;

ADENOVIRIDAE; CLINICAL TRIALS; DEFECTIVE VIRUSES; GENE THERAPY; GENETIC VECTORS; HUMAN; NEOPLASMS; VIRUS REPLICATION;

EID: 0035346819     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.3.525     Document Type: Article

References (60)

1. MERRITTJ, CLAYMAN G, SWISHERS eta!.: Clinical Phase I experience with INGN 201 (Ad-p53) in non-small cell lung cancer and head and neck cancer. Cancer Gene Ther. (1997) 4: S12. Abstract.
2. NEMUNAITIS J, BIER-LANING CM, COSTENLA-FIGUEIRAS M, YVER A, DREILING L: Three Phase II trials of intratumoral injection with a replication-deficient adenovirus carrying the p53 gene (AdCMV-p53) in patients with recurrent/refractory head and neck cancer. Pmc.Am. Soc. Clinical Res. (1999) 18:l66l.
3. KIRN D: Replication-selective micro-organisms: fighting cancer with targeted germ warfare. J. Clinical Invest. (2000) 105:836-838.
4. HEISE C, KIRN D: Replication-selective adenviruses as oncotytic agents./ ClinicalItwest.GOOÖ) 105:847-851.
5. PAWELEK J, LOW K, BERMUDES D: Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. (1997) 57:4537-4544.
6. HEISE C, WILLIAMS A, XUE S, PROPST M, KIRN D: Intravenous administration of ONYX-015, a selectivelyreplicating adenovirus, induces antitumoral efficacy. Cancer Res. (1999) 59:2623-2628.
7. KIRN D: Selectively-replicating viruses as therapeutic agents against cancer. Vol. 1. Academic Press (1998):235-248.
8. SMITH R, HUEBNER RJ, ROWE WP, SCHATTEN WE, THOMAS LB: Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer (1956) 9:1211-1218.
9. WEBB HE, SMITH CE: Viruses in the treatment of cancer. Lancet (1970) 1:1206-1208.
10. • 10. ASADA T: Treatment of human cancer with mumps virus. Cancer (1974) 34:1907-1928.
11. MARTUZA RL, MALICK A, MARKERT JM, RUFFNER KL, COEN DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (1991) 252:854-856.
12. MINETA T, RABKIN SD, MARTUZA RL: Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. (1994) 54:3963-3966.
13. MINETA T, RABKIN SD, YAZAKI T, HUNTER WD, MARTUZA RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. (1995) 1:938-943-
14. BISCHOFF JR, KIRN DH, WILLIAMS A etal: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 274:373-376.
15. HEISE C, SAMPSON JA, WILLIAMS A, MCCORMICK F, VON HD, KIRN DH: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cy to lys is and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med. (1997) 3:639-645.
16. LORENCE RM, KATUBIG BB, REICHARD KW et ah. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res. (1994) 54:6017-6021.
17. VAN PACHTERBEKE C, TUYNDER M, COSYN JP, LESPAGNARD L, LARSIMONT D, ROMMELAERE J: Parvovirus H-l inhibits growth of short-term tumor-derived but not normal mammary tissue cultures. Int.J. Cancer (1993) 55:672-677.
18. COFFEY M, STRONG J, FORSYTH P LEE P: Reovirus therapy of tumors with activated ras pathway. Science (1998) 282:1332-1334.
19. MASTRANGELO M, EISENLOHR L, GOMELLA L, LATTIME E: Poxvirus vectors: orphaned and under-appreciated. J. Clinical Invest. (2000) 105:1031-1034.
20. STOJDL DF, LICHTY B, KNOWLES S: Exploiting tumorspecific defects in the Interferon pathway with a previously unknown oncolytic virus. Nature Med. (2000) 6:821-825.
21. WOLD WS, HERMISTON TW, TOLLEFSON AE: Adenovirus proteins that subvert host defenses. Trends Microbiol. (1994) 2:437-443.
22. SPARER TE, TRIPP RA, DILLEHAY DL et al: The role of human adcnovirus early region 3 proteins (gp!9K, 10.4K, 14.5K and 14.7K) in a murine pneumonia model J. Virol. (1996) 70:2431-2439.
23. MARTUZA RL, MALICK A, MARKERT JM, RUFFNER KL, COEN DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. (1991) 252:854-856.
24. MINETA T, RABKIN SD, YAZAKI T, HUNTER WD, MARTUZA RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. (1995) 1:938-943.
25. BARKER DD, BERK AJ: Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology (.1987) 156:107-121.
26. GANLY I, SOUTAR D, BROWN R, KAYE S: p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy. Br. J. Cancer (2000) 82:392-398.
27. SCHEFFNER M, MUNGER K, BYRNE JC, HOWLEY PM: The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sei. USA (1991) 88:5523-5527.
28. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B, HARRIS CC: p53 mutations in human cancers. Science (1991) 253:49-53.
29. HARADA J, BERK A: p53-independent and -dependent requirements for ElB-55kD in adenovirus Type 5 replication.J. Virol. (1999) 73:5333-5344.
30. ROGULSKI K, FREYTAG S, ZHANG K et a!.: In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. (2000) 60:1193-1196.
31. RIES SJ, BRANDTS CH, CHUNG AS et al.: Loss of pl4ARF in tumor cells facilitates replication of the adenovims mutant 1520 (ONYX-015). Nature Med. (2000) 6:1128-1133.
32. GOODRUM FD, ORNELLES DA: The early region IB 55-kilodalton oncoprotein of adenovims relieves growth restrictions imposed on viral replication by the cell cycle./ Virol. (1997) 71:548-561.
33. ROTHMANN T, HENGSTERMANN A, WHITAKER NJ, SCHEFFNER M, ZUR HAUSEN H: Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells./ Virol. (1998) 72:9470-9478.
34. HALL AR, DK BR, O'CARROLL SJ, BRAITHWAITE AW: p53-dependent cell dcath/apoptosis is required for a productive adenovirus infection [sec comments]. Nature Med. (1998) 4:1068-1072.
35. GANLY I, KIRN D, ECKHARDT S, RODRIGUEZ G et al.: A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. (2000) 6:798-806.
36. HECHT JR, ABBRUZZESE J, BEDFORD R, LAHOTI S, KIRN D: A Phase I study of multiple direct injections of ONYX-015 adenovirus under endoscopie ultrasound guidance. Proc. Am. Soc. Clin. Oncol. (1999) 18:186.
37. NEMUNAITIS J, GANLY I, KHURI F, ARSENAU J, KAYE S, KIRN D: Selective replication and oncoh/sis In p53 mutant tumors with Onyx-015, an ElB-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a Phase II trial. Cancer Res. (2000) 60:6359-6366.
38. HECHT R, ABBRUZZESE J, BEDFORD R et a!.: A Phase I/H trial of intratumoral endoscopie injection of Onyx-015 with intravenous gemcitabine hi unresectable pancreatic carcinoma. Proc. Am. Soc. Clin. Oncol. (2000) 19:1039. Abstract.
39. KIRN DH, KHURI F, GANLY I et al.: A Phase II trial of ONYX-015, a selectively-replicating adenovirus, In combination with cisplatin and 5-fiuorouracil hi patients with recurrent head and neck cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:1505.
40. VASEY p, SHULMANL, GORE M, KIRN D, KAYE S: Phase I trial of intraperitoneal Onyx-015 adenovirus in patients with recurrent ovarian carcinoma. Proc. Am. Soc. Clin. Oncol. (2000) 19:1512. Abstract.
41. REID T, GALANIS E, ABBRUZZESE J, ROMEL L, RUBIN J, KIRN D: Hepatic artery infusion of Onyx-015, a replication-selective adenovirus, hi combination with 5-FU/leucovorin for gastrointestinal carcinoma metastaüc to the liver: a Phase I/n clinical trial Proc. Am. Soc. Clin. Oncol. (2000) 19:953. Abstract.
42. NEMUNAITIS J, CUNNINGHAM C, RANDLEV B, KIRN D: A Phase I dose escalation trial of intravenous infusion with a replication-selective adenovirus, 411520, in patients with refractory cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:724. Abstract.
43. KHURI F, NEMUNAITIS J, GANLY I, KAYE S, HONG W, KIRN D: A controlled trial of Onyx-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer. Nature Meet. (2000) 6:879-885.
44. KIRN D, NEMUNAITIS J, GANLY I, POSNER M, YOKES E, KAYE S: A Phase II trial of intratumoral injection with an ElB-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer. Proc. Am. Soc. Clin. Oncol. (1998) 17:391a.
45. HEISE C, SAMPSON-JOHANNES A, WILLIAMS A, MCCORMICK F, VON HOFF DD, KIRN DH: ONYX-015, an E1B gene-attenuated adenovirus, causes tumorspecific cytotysis and antirumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med. (1997) 3:639-645.
46. HEISE C, LEMMON M, KIRN D: Replication-selective adenovirus plus cisplatin chemotherapy efficacy is dependent on sequencing but independent of p53 status. Clin. Cancer Res. 2000 (In Press).
47. GOODRUM FD, ORNELLES DA: p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus h/tic infection./ Virol. (1998) 72:9479-9490.
48. DOBNER T, HORIKOSHI N, RUBENWOLF S, SHENK T: Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science (1996) 272:1470-1473.
49. YEW PR, LIU X, BERK AJ: Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53. Genes Dev. (1994) 8:190-202.
50. DOBBELSTEIN M, ROTH J, KIMBERLY WT, LEVINE AJ, SHENK T: Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence. EMBOJ. (1997) 16:4276-4284.
51. GOODIN LR: Regulation of TNF-mediated cell death and inflammation by human adenoviruses. Infect. Agents Dis. (1994) 3:106-115.
52. HEIS C, HERMISTON T, WILLIAMS M, KIRN D: An adenovirus E1A mutant with potent and selective systemic anti-tumoral efficacy. Nature Ated. 6(10):1134-1141.
53. FUEYO J, GOMEZ-MANZANO C, ALEMANY R et al: A mutant oncolytic adenovirus targeting the Kb pathway produces anti-glioma effect in vivo. Oncogens (2000) 19:2-12.
54. HAWKINS L, NYE J, CASTRO D, JOHNSON L, KIRN D, HERMISTON T: Replicating adcnoviral gene therapy. Proc. Am. Assoc. Cancer Res. (1999) 40:3145. Abstract.
55. FREYTAG SO, ROGULSKI KR, PAIELLI DL, GILBERT JD, KIM JH: A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene and radiotherapy. Hum. Gene Tber. (1998) 9:1323-1333.
56. WILDNER O, BLAESE RM, MORRIS JM: Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidinc kinasc. Cancer Res. (1999) 59;4lO-U3.
57. BOVIATSIS EJ, PARK JS, SENA-ESTEVES M et al.: Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. (1994) 54:5745-5751.
58. ROELVINK P, MI G, EINFELD D, KOVESDI I, WICKHAM T: Identification of a conserved reseptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science (1999) 286:1568-1571.
59. LATTIME EC, LEE SS, EISENLOHR LC, MASTRANGELO MJ: In situ cytokinc gene transfection using vaccinia virus vectors. Semin. Oucol. (1996) 23:88-100.
60. LOW K, ITTENSOHN M, LE T et al: Lipid A mutant salmonella with suppressed virulence and TNF-alpha induction retain tumor-targeting in vivo. Nature Biotecb. (1999) 17:37-41.